Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD8 T cell PET imaging with 89Zr-Df-crefmirlimab in giant cell arteritis and rheumatoid arthritis
2022-002822-28Phase 2Active
- Sponsor
- University Medical Center Groningen
- Start
- Nov 2022
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label trial of [89Zr]Zr-Df-Crefmirlimab in giant cell arteritis (GCA) and rheumatoid arthritis (RA) (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Arterial and synovial 89Zr-Df-crefmirlimab uptake on PET/CT. Started Nov 2022; status: active.
02
Drugs
[89Zr]Zr-Df-Crefmirlimab
03
Conditions
giant cell arteritis (GCA)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2022-002822-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002822-28.